"Ranibizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A recombinant humanized monoclonal antibody fragment that binds VEGF-A to prevent its binding to VEGFR-1 and VEGFR-2 receptors. This activity reduces vessel permeability and angiogenesis in the treatment of neovascular age-related MACULAR DEGENERATION.
| Descriptor ID |
D000069579
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.868 D12.776.124.790.651.114.224.060.868 D12.776.377.715.548.114.224.200.868
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ranibizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Ranibizumab [D12.776.124.486.485.114.224.060.868]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Ranibizumab [D12.776.124.790.651.114.224.060.868]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Ranibizumab [D12.776.377.715.548.114.224.200.868]
Below are MeSH descriptors whose meaning is more specific than "Ranibizumab".
This graph shows the total number of publications written about "Ranibizumab" by people in this website by year, and whether "Ranibizumab" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ranibizumab" by people in Profiles.
-
Patient adherence to therapy after switch to aflibercept from bevacizumab or ranibizumab for treatment-refractory neovascular age-related macular degeneration. Indian J Ophthalmol. 2024 Jan 01; 72(Suppl 1):S101-S105.
-
Intraocular pressure decreases in eyes with glaucoma-related diagnoses after conversion to aflibercept for treatment-resistant age-related macular degeneration. Eye (Lond). 2022 Sep; 36(9):1813-1819.
-
Five-Year Real-World Outcomes of Occult and Classic Choroidal Neovascularization: Data From the Fight Retinal Blindness! Project. Am J Ophthalmol. 2019 08; 204:105-112.
-
Mycobacterium chelonae Scleral Abscess After Intravitreal Ranibizumab Injection. Cornea. 2016 Aug; 35(8):1136-7.
-
Effects of core vitrectomy in the treatment of age-related macular degeneration. Acta Ophthalmol. 2014 Aug; 92(5):465-72.